CLYM Q2 2023 Earnings — Climb Bio, Inc. Revenue & Financial Results | Market Cap Arena

CLYMClimb Bio, Inc.

$522M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$5M

EPS (Diluted)

$-0.19

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$777,000

Balance Sheet

Total Assets

$116M

Total Liabilities

$4M

Stockholders' Equity

$113M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$14M	+51.0%
Net Income	-$5M	-$15M	+64.2%